Evers S., Olesen J. Botulinum toxin in headache treatment: the end of the road. Cephalalgia 2006 ; 26: 769-771.
Delstanche S., Schoenen J. La toxine botulinique dans le traitement des cphales: Fin de route ou dbut d'un chemin? Neurone 2006 ; 11: 148-154.
Aurora SK, DW Dodick, Turkel CC et al. on behalf of PREEMPT 1 Chronic Migraine Study Group. Onabotulinum toxin A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010 17 March (DOI: 10.1177/0333102410364676).
Diener HC, Dodick DW, Aurora SK, et al. on behalf of the PREEMPT 2 Chronic Migraine Study Group. Onabotulinum toxin A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010 17 March (DOI: 10.1177/0333102410364677).
Olesen J., Bousser M-G., Diener H-C., et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006 ; 26: 742-746.
Manack A., Turkel C., Silberstein S. The evolution of chronic migraine: Classification and nomenclature. Headache 2009 ; 49: 1206-1213.
Silberstein S., Lipton R., Dodick D., et al. Topiramate treatment of chronic migraine: A randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009 ; 49: 1153-1162.
Mathew NT, Jaffri SFA. A double-blind comparison of Onabotulinum toxin A (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: A pilot study. Headache 2009 ; 49: 1466-1478.
